The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
iPSC Phenotyping Environmental Exposure Program, 2025Screening the Functional Impact of Environmental Chemicals on Human Neurons and Astrocytes in Culture
Study Rationale: With growing global concerns about environmental chemicals acting as a trigger of Parkinson's disease (PD), we will assess the affect such molecules have on the electrical activity...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
Study Rationale: Although levodopa is an effective treatment for Parkinson’s disease (PD), it has a debilitating on-target side effect of dyskinesia. An optimal PD therapy would selectively activate...
-
, 2022Uncovering Proteomic Alterations in Parkinson’s Disease Using Patient-specific iPSC-derived Brain Cells
Study Rationale: Transgenic small models have been used as gold standard to study human brain diseases, but it is unclear how conclusive and faithfully these models reflect pathophysiological...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Translational Investigation of Drugs that Modulate Circadian Rhythm in Models of Parkinson’s Disease
Study Rationale: Recent studies suggest that sleep problems can worsen Parkinson’s disease (PD) by affecting chemicals in the brain and causing inflammation. It's also possible that sleep problems...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Developing Novel Lysosome-based Translational Biomarkers and Ion-Channel Agonists as Therapeutics for Parkinson’s Disease
Study Rationale: Lysosomal dysfunction impairs cells’ ability to recycle their damaged components and is a primary contributor to the progression of Parkinson's disease (PD). TMEM175, a novel ion...
-
iPSC Phenotyping Environmental Exposure Program, 2024Phenotyping Environmental Exposure to Long-lasting Chemicals, Nanoplastics and Pesticides in iPSC Dopaminergic Neurons and Glia
Study Rationale: Of high priority is a need to understand the impact of pesticides, emerging long-lived chemicals, Per- and Polyfluoroalkyl Substances, and nanoplastics on neurons and glial cells and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.